Translating world leading research in NMT into a pipeline of first-in-class ADC medicines for cancer
Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival.
Investors
A private company, Myricx is backed by a syndicate of experienced investors including Brandon Capital Partners and Sofinnova Partners.
Location
Myricx is located near the Francis Crick Institute, close to our co-founder’s lab.